ANONDITA

Anondita Medicare Limited

Listed company · ISIN INE0VTV01012 · NSE SM · FV ₹10
Last price
₹946
+0.38%today
What this company does

Anondita Medicare Limited is a listed company. It booked ₹83 cr of revenue in its latest half year (H2 FY26) and kept 25.5% of sales as profit.

63out of 100
Equitytale Health Score
Mixed

Healthier than 63% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,387–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
36

At close. Not part of the score.

Profitability & returns93

How much profit it earns on the money it employs

Balance sheet64

How much it owes, and whether earnings cover the interest

Cash quality34

Whether reported profit actually arrives as cash

Valuation15

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Strong 26% net margin
✓ Promoters hold 59%
✓ No promoter shares pledged
✓ Strong 38% return on equity
Watch-outs
None flagged from our data

What if I invest in ANONDITA?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹946▲ +0.38%
latest close · 2026-11-04
52-wk low ₹92174 sessions so far52-wk high ₹1,190
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio41.5High
LowAverageHigh
P/B ratio15.39High
Below bookModerateHigh
EV / EBITDA27.9High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity38.3%Strong
WeakFairStrong ▸15%
Return on capital39.7%Strong
WeakFairStrong
Net margin25.5%Strong
ThinDecentStrong
EBITDA margin37.5%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.30Comfortable
LowModerateHigh ▸1
Interest cover18.2×Strong
RiskyOkayStrong ▸5×
Current ratio3.57Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹1,710 cr
Book value
₹61
EPS
₹11.38
latest half year
Net debt
₹33 cr
owes more than its cash
Enterprise value
₹1,744 cr
EBITDA
₹62 cr
annualised
EBIT
₹62 cr
annualised
Operating margin
37.5%
Return on assets
23.0%
Earnings yield
2.41%
P/S
10.26
Sales / share
₹92.1
Tax rate
27.9%
Face value
₹10
Shares
1.8 cr
Working capital
₹71 cr
Current assets
₹99 cr
Current liabilities
₹28 cr
Delivery %
72.5%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹165–₹165, midpoint ₹165

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹83 cr
Other Income₹43.5 L
Total Income₹84 cr
Cost of Materials₹29 cr
Purchases of Stock-in-Trade₹12 cr
Inventory Change (±)₹-5 cr
Employee Benefit Expense₹5 cr
Finance Costs₹2 cr
Other Expenses₹11 cr
Total Expenses₹54 cr
Profit before Tax₹30 cr
Tax Expense₹8 cr
Net Profit₹21 cr
Net margin on total income25.4%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹36 cr42.6%
Employee benefit expense₹5 cr5.8%
Finance costs₹2 cr2.0%
Other expenses₹12 cr14.3%
Tax expense₹8 cr9.8%
Profit for the period₹21 cr25.4%
Total income ₹84 cradds up to ₹100 ✓
Half-yearly results · consolidated (₹ cr)
MetricH1 FY26H2 FY26
Revenue54 cr83 cr
Total income55 cr84 cr
Expenses37 cr54 cr
Profit before tax17 cr30 cr
Tax4 cr8 cr
Net profit (owners' share)13 cr21 cr
Net margin (owners' share, on revenue)24.1%25.5%
EPS (₹)9.1211.38
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹185 cr
Shareholder equity
₹111 cr
parent shareholders
Total debt
₹34 cr
Cash
₹25.2 L
Corporate actions
ActionDetailEx-date
Rights issue1831:972 Sep 2026
Who owns it · 2026-10-05
No pledge
Promoter
59.3%
FII / Foreign
2.5%
DII / Domestic
6.0%
Retail / others
32.2%
Promoter stake down 2.5% over the last 4 quarters.
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 29 Sep 2026
See the official result
1
To consider and adopt the audited standalone and consolidated financial statements of the company for the financial year ended 31st March 2026, together with the reports of the board of directors and auditors thereon.
Backed by 100% of shareholders other than promotersneeded 50%
1.95 L votes for, 0 against
2
To appoint a director in the place of Mr. Lakhinder Singh (DIN: 07703780) who retires by rotation in terms of section 152(6) of the Companies Act, 2013, and being eligible, offers himself for re-appointment
Backed by 100% of shareholders other than promotersneeded 50%
1.95 L votes for, 0 against
3
To ratify the remuneration of cost auditors for the financial year ending 31st march 2027
Backed by 100% of shareholders other than promotersneeded 50%
1.95 L votes for, 0 against
4
Approval for material modification of earlier approved material related party transaction(s) with Anondita Healthcare & Rubber Products India limited (“AHRPIL”/ “subsidiary”):
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 50%
1.95 L votes for, 0 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 16 named members
owning 59.3% between them · as of 2026-10-05
ANUPAM GHOSH58.87%
RESHANT GHOSH0.24%
SONIA GHOSH0.16%
All India Condom Manufacturer Associationno shares
ANAYA GHOSHno shares
ANIL SHARMAno shares
ANISHA GHOSHno shares
Anondita Exultia Healthcare Private Limitedno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it
1 fundraise spent differently than promised

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹69 cr raised in Aug 2025 by selling shares to the public
⚑ company reported a change of plan

As of Mar 2026, the company says it has spent 89% of what it set aside, leaving ₹7 cr still to be spent. Infomerics Valuation and Rating Limited watches the spending on the exchange’s behalf.

“As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 andDecember31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly: • An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisitionwas revised from ₹2015.87 Lakhs to ₹1737.46Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.”the company’s own explanation, as filed · shareholders approved the change
Capex
now filed as: No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus
44%
₹3 cr of ₹6 cr
Funding Working Capital Requirements
now filed as: Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company’s working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company’s expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025–26, which has now been revised to approximately ₹145 crore.
originally ₹35 cr
budget changed
95%
₹36 cr of ₹38 cr
General Corporate Purpose (GCP) 1. for Unidentified Acquisition 2. For GCP (Capped at 25% of gross issue size)
now filed as: Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company’s working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company’s working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27, it was subsequently expected that the entire allocation would be deployed within FY 2025–26. However, the balance amount shall now be utilized during the current financial year 2026–27.
originally ₹20 cr
budget changed
93%
₹16 cr of ₹17 cr

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.